ALIMTA
Drug
Lilly USA, LLC
Total Payments
$937,262
Transactions
10,594
Doctors
3,788
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $43.93 | 2 | 2 |
| 2022 | $48,008 | 46 | 34 |
| 2021 | $56,441 | 136 | 108 |
| 2020 | $55,995 | 1,108 | 847 |
| 2019 | $336,251 | 4,770 | 2,149 |
| 2018 | $145,922 | 1,058 | 739 |
| 2017 | $294,600 | 3,474 | 1,902 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $343,937 | 8 | 36.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $259,325 | 152 | 27.7% |
| Food and Beverage | $156,159 | 10,139 | 16.7% |
| Consulting Fee | $149,025 | 78 | 15.9% |
| Travel and Lodging | $24,490 | 167 | 2.6% |
| Education | $4,326 | 50 | 0.5% |
Payments by Type
General
$593,325
10,586 transactions
Research
$343,937
8 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TREATMENT OF RECURRENT PRIMARY OR SECONDARY CENTRAL NERVOUS SYSTEM (CNS) LYMPHOMA WITH ALIMTA (PEMETREXED) | Lilly USA, LLC | $54,000 | 0 |
| RANDOMIZED PHASE III STUDY OF MAINTENANCE THERAPY WITH BEVACIZUMAB PEMETREXED, OR A COMBINATION OF BEVACIZUMAB AND PEMETREXED FOLLOWING CARBOPLATIN, PACLITAXEL AND BEVACIZUMAB FOR ADVANCED NON-SQUAMOUS NSCLC | Lilly USA, LLC | $47,177 | 0 |
| A STUDY OF PEMETREXED PLUS CARBOPLATIN FOLLOWED BY MAINTENANCE PEMETREXED VS PACLITAXEL PLUS CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB IN PATIENTS WITH ADVANCED NCSLC OF NONSQUAMOUS HISTOLOGY | Lilly USA, LLC | $36,680 | 1 |
| RETRO ANALYSIS-GENOMIC LANDSCAPE NSCLC PRIOR TO PEMETREXED | Lilly USA, LLC | $6,080 | 0 |
Top Doctors Receiving Payments for ALIMTA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $340,340 | 8 |
| , M.D | Internal Medicine | Lexington, KY | $48,938 | 61 |
| , M.D | Medical Oncology | Greensboro, NC | $36,981 | 66 |
| , M.D | Hematology & Oncology | Orlando, FL | $31,313 | 26 |
| , M.D | Hematology & Oncology | Scottsdale, AZ | $27,622 | 45 |
| , MD | Hematology & Oncology | Conroe, TX | $24,016 | 63 |
| , MD, MPH, MBA | Hematology & Oncology | Chicago, IL | $23,566 | 28 |
| , M.D | Medical Oncology | Kittanning, PA | $22,845 | 25 |
| , MD | Hematology & Oncology | Encino, CA | $22,740 | 50 |
| , MD | Hematology & Oncology | Pittsburgh, PA | $20,204 | 11 |
| , MD | Hematology & Oncology | Louisville, KY | $19,151 | 20 |
| , MD | Medical Oncology | Grand Rapids, MI | $16,872 | 28 |
| , M.D | Hematology & Oncology | Miami, FL | $14,796 | 20 |
| , MD | Hematology | Stamford, CT | $14,561 | 29 |
| , MD | Medical Oncology | El Paso, TX | $14,367 | 26 |
| , M.D | Hematology & Oncology | Beverly Hills, CA | $12,426 | 21 |
| , MD | Hematology & Oncology | Atlanta, GA | $9,977 | 15 |
| , MD | Medical Oncology | Jackson, MS | $8,540 | 14 |
| , MD | Internal Medicine | Philadelphia, PA | $6,650 | 2 |
| , MD | Medical Oncology | Olney, MD | $5,418 | 5 |
| , M.D | Hematology | Ocala, FL | $5,190 | 11 |
| , MD | Hematology & Oncology | Washington, DC | $4,457 | 3 |
| , M.D | Internal Medicine | Pascagoula, MS | $4,218 | 13 |
| , MD | Hematology & Oncology | Galveston, TX | $3,825 | 1 |
| , MD | Hematology & Oncology | Burlington, NC | $3,620 | 1 |
Ad
Manufacturing Companies
- Lilly USA, LLC $722,861
- Eli Lilly and Company $207,888
- Eli Lilly Export S.A. Puerto Rico Branch $6,513
Product Information
- Type Drug
- Total Payments $937,262
- Total Doctors 3,788
- Transactions 10,594
About ALIMTA
ALIMTA is a drug associated with $937,262 in payments to 3,788 healthcare providers, recorded across 10,594 transactions in the CMS Open Payments database. The primary manufacturer is Lilly USA, LLC.
Payment data is available from 2017 to 2023. In 2023, $43.93 was paid across 2 transactions to 2 doctors.
The most common payment nature for ALIMTA is "Unspecified" ($343,937, 36.7% of total).
ALIMTA is associated with 4 research studies, including "TREATMENT OF RECURRENT PRIMARY OR SECONDARY CENTRAL NERVOUS SYSTEM (CNS) LYMPHOMA WITH ALIMTA (PEMETREXED)" ($54,000).